Intangible Assets, Earn-Outs in BioPharma Acquisitions
Sorbus Advisors LLC studied purchase price allocations in biopharmaceutical industry titled “Valuation of Goodwill and Intangibles in 2015 BioPharmaceutical Transactions.” The study focused on recognition, valuation, and determination of useful lives of pertinent intangible assets, contingent considerations and goodwill. While no two acquisitions are the same, common themes in the valuation of intangibles and goodwill